drugset
drugset / Trial / NCT02556788

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02556788 ↗

Phase 3 Completed 1212 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Timeline

Start
2015-11
Primary completion
2017-02-07
Completion
2017-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 50 unknown —

Indications

acne